
AbbVie Set to Acquire Cerevel Therapeutics in $8 Billion Deal
AbbVie Inc is reportedly close to finalizing an $8 billion deal to acquire Cerevel Therapeutics Holdings Inc, a drug developer specializing in neurological conditions like Parkinson's. This potential acquisition comes shortly after AbbVie's agreement to purchase cancer drug developer ImmunoGen Inc for $10.1 billion, indicating the company's interest in investing in promising new medicines. The deal, which is being negotiated at around $45 per share, could be announced as early as this week.
